METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer to Accelerate Global Expansion and Commercialization

Mar 03, 2025 15:15 CST Updated 15:15

METiS TechBio

AI-Driven Drug Formulation Developer

METiS TechBio, an innovative biotechnology company focused on "AI + drug delivery," announced the appointment of Mark Herbert as Chief Business Officer (CBO), effective January 22, 2025.Mark Herbert will be responsible for global business development, and his joining marks METiS TechBio's entry into a brand-new phase of development. The company will further enhance its business development capabilities, accelerate the commercialization process, and promote innovative therapies to the global market.

METiS TechBioChief Business Officer Mark Herbert

Mark Herbert's Outstanding Background and Experience

Mark Herbert has over 20 years of extensive experience in the biotechnology field, having served in senior executive positions at several well-known biotech companies, successfully driving numerous significant collaborations and commercialization projects.

Before joining METiS TechBio, he served as the President of Arcturus Therapeutics, leading the company’s deep collaborations with Takeda Pharmaceutical and CureVac on platforms and mRNA pipelines, creating over $2 billion in cumulative partnership value. Additionally, he served as Vice President of Business Development at Varda Space Industries, Chief Commercial Officer at Scientist.com, and gained extensive industry experience at prominent companies such as WuXi AppTec and Aragon Pharmaceuticals.

Mark Herbert’s addition will bring deep industry resources and a global perspective to METiS TechBio, further strengthening business development capabilities, deepening global partnerships, and accelerating the commercialization of innovative therapies.

Joining Hands with Global Partners, METiS TechBio Advances into a New Phase of Commercialization

METiS TechBio has made remarkable progress in the past year, especially in the field of LNP (lipid nanoparticle) delivery technology. It has established a globally leading "AI + nanomaterials" technology platform and achieved breakthrough success in the development of targeted nano-delivery materials. The company pioneered multi-organ targeted delivery to the heart, muscles, brain, and other organs, with delivery efficiency to the liver, lungs, and other organs improved more than 20 times over industry standards, overcoming the "bottleneck" challenge of precise RNA drug delivery. Meanwhile, METiS TechBio has engaged in deep collaborations with over 20 top global pharmaceutical and biotechnology companies, jointly driving innovation in the industry.

Regarding joining METiS TechBio, Mark Herbert stated: “I am deeply honored to join the talented team at METiS TechBio. I look forward to working closely with the team to drive innovation in advanced nucleic acid therapies and drug delivery technologies, while expanding global partnerships. METiS TechBio is at the forefront of leveraging AI to revolutionize drug delivery, and I am thrilled to be part of this exciting journey.”

Dr. Lai Caida

Co-founder & CEO of METiS TechBio

We are thrilled to welcome Mark Herbert to METiS TechBio. Mark is a seasoned executive with extensive experience in the biotech industry, boasting an outstanding track record in business development and commercialization. His leadership will be pivotal in strengthening our partnerships and exploring new growth opportunities, injecting strong momentum into the next phase of METiS TechBio's development.

Academician Chen Hongmin

Co-founder of METiS TechBio&CRDO

Business development is a crucial part of METiS TechBio's move towards commercialization. As Chief Business Officer, Mark will lead the team in deepening global partnerships. With the company’s rapid growth, we will continue to strengthen our business development capabilities, working with global partners to advance innovative delivery technologies and bring breakthrough therapies to patients more quickly.

With the joining of Mark Herbert, METiS TechBio is poised to embark on a new chapter of development. Moving forward, the company will continue to focus on delivering transformative therapeutic solutions to patients worldwide through innovative delivery technologies.

About METiS TechBio (METiS)Pharmaceuticals）

METiS TechBio (METiS Pharmaceuticals) was founded in 2020 as an innovative biotechnology company driven by artificial intelligence (AI) to advance drug delivery and drug discovery.

METiS TechBio aims to drive the development of innovative drugs more efficiently and precisely by integrating cutting-edge technologies such as novel AI, machine learning, and quantitative simulations with drug discovery. This enables more effective design of innovative delivery materials, selection of drug candidates, formulation design, development of "programmable nucleic acid drugs," and nucleic acid delivery design, bringing revolutionary medicines to patients worldwide and addressing unmet clinical needs.

Learn More About METiS TechBio

METiS TechBio 2024 Year-End Review | AI Surge Propels RNA into a New Era

METiS TechBio Scientists Discuss miRNA, RNAi, and mRNA Technologies

From AI Sweeping the Nobel Prize to Industry Trends: METiS TechBio's Reflections and Forecasts